Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
62 hedge funds and large institutions have $508M invested in Evelo Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 12 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
158% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 12
27% more funds holding
Funds holding: 49 → 62 (+13)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% less capital invested
Capital invested by funds: $508M → $508M (-$393K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $168K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.5M |
| 2 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$12.4M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$11.1M |
| 4 |
BlackRock
New York
|
+$4.55M |
| 5 |
AG
Artal Group
Luxembourg
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$326K |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$145K |
| 3 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$79K |
| 4 |
Jane Street
New York
|
-$66.9K |
| 5 |
PCA
Peddock Capital Advisors
Braintree,
Massachusetts
|
-$44K |
EVLO Hedge Fund Activity: Q1 2021 in Review
62 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q1 2021, worth a combined $508M — down 0.08% from $508M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new EVLO positions and 2 closed out — a net gain of 13 holders — while 31 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $16.5M. The largest seller was Morgan Stanley, cutting an estimated $326K.
- 62 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q1 2021, up from 49 in Q4 2020.
- Funds reported $508M of Evelo Biosciences, Inc. Common Stock stock for Q1 2021, down 0.08% quarter-over-quarter.
- 15 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q1 2021 and 2 closed out, a net change of +13 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q1 2021 was Fidelity Investments, an estimated $16.5M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q1 2021 was Morgan Stanley, an estimated $326K sold.
Based on aggregated 13F filings for Q1 2021.